地拉罗司 说明书

Deferasirox (Enriga) is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron anthelmintic approved by the US FDA for routine use. It is approved for use in patients ≥2 years old with chronic iron overload caused by blood transfusion. The therapeutic effect of Deferasirox (Enrige) is remarkable, and the successful development of this drug is good news for many patients.

Some patients may experience diarrhea/vomiting/headache/abdominal pain/increased liver enzymes/cough/throat inflammation/urticaria/fever/rash/increased serum creatinine when using Deferasirox (Enrig). Therefore, we must pay attention to this aspect. If the adverse reactions are serious, everyone should operate under the guidance of a doctor. Knowing its precautions, we should be more careful when using drugs. Reasonable use of drugs is helpful to our health. It is recommended that everyone pay attention to this aspect. Patients should undergo detailed examination before receiving deferasirox (Enrige) treatment and strictly follow the doctor's diagnosis and treatment recommendations.

The recommended dosage of Deferasirox (Enrig) is 20 to 30 mg/kg per day, once a day. Patients should note that Deferasirox (Enrig) should be taken on an empty stomach at least 30 minutes before meals, once a day, and at the same time every day. Patients should not chew the tablets while taking this medicine. Deferasirox (Enreg) should not be administered concurrently with aluminum-containing antacids. And deferasirox (Enrige) cannot be combined with other iron chelation treatments. Patients who are allergic to any of the ingredients in Deferasirox should not take this medicine for treatment. Deferasirox (Enrige) may cause a rash. Generally, the rash will disappear automatically without the need to adjust the dosage or stop taking the medication; however, patients should stop taking the medication if the condition is severe or persistent.

The above is the introduction about Deferasirox (Enrego), I hope it can help everyone. If patients have other questions about the drug, they can consult the medical companion service.